These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11711744)

  • 1. Age-related cancer detection rate and costs for one cancer detected in one screening by immunochemical fecal occult blood test.
    Nakama H; Zhang B; Zhang X; Fukazawa K
    Dis Colon Rectum; 2001 Nov; 44(11):1696-9. PubMed ID: 11711744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of cancer detection rate and costs of one cancer detected among different age-cohorts in immunochemical occult blood screening.
    Nakama H; Zhang B; Fukazawa K; Zhang X
    J Cancer Res Clin Oncol; 2001 Jul; 127(7):439-43. PubMed ID: 11469681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer.
    Nakama H; Zhang B; Zhang X
    Eur J Cancer; 2001 Feb; 37(3):398-401. PubMed ID: 11239763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer.
    Nakama H; Zhang B; Fattah AS
    Eur J Cancer; 2000 Mar; 36(5):647-50. PubMed ID: 10738130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening.
    Greenwald B
    Gastroenterol Nurs; 2005; 28(2):90-6. PubMed ID: 15832108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for colorectal cancer: current status in Japan.
    Saito H
    Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
    Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
    Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy.
    Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
    Dig Liver Dis; 2018 Mar; 50(3):254-259. PubMed ID: 29198569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemical fecal occult blood test is not suitable for diagnosis of hemorrhoids.
    Nakama H; Kamijo N; Fujimori K; Horiuchi A; Abdul Fattah S; Zhang B
    Am J Med; 1997 Jun; 102(6):551-4. PubMed ID: 9217670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods.
    Yamamoto M; Nakama H
    Hepatogastroenterology; 2000; 47(32):396-9. PubMed ID: 10791199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of colorectal cancer screening methods in Iran.
    Allameh Z; Davari M; Emami MH
    Arch Iran Med; 2011 Mar; 14(2):110-4. PubMed ID: 21361717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening.
    Zhang B; Fattah A; Nakama H
    Hepatogastroenterology; 2000; 47(32):414-8. PubMed ID: 10791202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia.
    Nakama H; Yamamoto M; Kamijo N; Li T; Wei N; Fattah AS; Zhang B
    Hepatogastroenterology; 1999; 46(25):228-31. PubMed ID: 10228797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.